1. Stocks
    2. /
  2. Neuren Pharmaceuticals Limited (ASX: NEU)
    3. /

Neuren Pharmaceuticals Limited (ASX: NEU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Neuren Pharmaceuticals Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Neuren Pharmaceuticals Limited (ASX: NEU)
    Latest News

    Scientist looking at a laptop thinking about the share price performance.
    Healthcare Shares

    Why this high-flying ASX 200 healthcare stock just crashed 11%

    | Bronwyn Allen

    Neuren Pharmaceuticals just dropped its 1Q FY24 report on DAYBUE sales.

    Read more »

    two magicians wearing dinner suits with bow ties wave their magic wands over a levitating bag with a dollars sign on it.
    Investing Strategies

    3 ASX shares to help turn $100,000 into $1 million

    | Tony Yoo

    Compounding and growth stocks can help you pull off what other people might think is a magic act.

    Read more »

    A businessman holding a butterfly net looks around hoping to snare a good ASX share investment
    Best Shares

    Top ASX shares to buy in April 2024

    | Motley Fool Staff

    Our Foolish writers are chock-full of stock ideas this month!

    Read more »

    Doctor doing a telemedicine using laptop at a medical clinic
    Cheap Shares

    1 secretly cheap ASX 200 stock I'm buying for the long run

    | Tony Yoo

    The best performer on the index last year has had a poor start to 2024. Let's examine whether this is…

    Read more »

    A couple consider the pros and cons of taking out a loan
    Value Investing

    3 ASX stocks boasting better margins than Nvidia

    | Mitchell Lawler

    Think you can't find Nvidia-like margins among Aussie shares... think again.

    Read more »

    A person sitting at a desk smiling and looking at a computer.
    Investing Strategies

    The best ASX shares to invest $500 in right now

    | Tony Yoo

    Creating wealth isn't just for the privileged. Just a few hundred dollars can get you started in stock investing.

    Read more »

    A woman's hand draws a stylised 'Top Ten' on a projected surface.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was an awful end to the trading week for ASX investors this Friday.

    Read more »

    Rising gold share price represented by a green arrow on piles of gold block.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a volatile, but positive day for the stock market this Tuesday.

    Read more »

    A young boy sits on his father's shoulders as they flex their muscles at sunrise on a beach
    Investing Strategies

    $10k of savings? I'd buy these ASX 200 shares to grow my money

    | Tony Yoo

    I would choose the stocks based on whether the company seems likely to be doing better in five years' time…

    Read more »

    Man leaps as he runs along the street.
    Investing Strategies

    4 Australian shares set to soar in 2024

    | Tony Yoo

    These stocks are looking great for a bull run this year, but for vastly different reasons.

    Read more »

    A young woman holding her phone smiles broadly and looks excited, after receiving good news.
    Broker Notes

    Leading brokers name 3 ASX shares to buy today

    | James Mickleboro

    Here's why brokers believe that now could be the time to snap up these shares.

    Read more »

    Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.
    Earnings Results

    Which ASX shares delivered the biggest profit jumps of the earnings season?

    | Bronwyn Allen

    These companies revealed at least a 70% profit boost in their latest earnings reports.

    Read more »

    Frequently Asked Questions

    No, Neuren Pharmaceuticals does not pay dividends at this time. 

    Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Neuren Pharmaceuticals Limited

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    Profile

    since

    Note